Compare · COEP vs RVMD
COEP vs RVMD
Side-by-side comparison of Coeptis Therapeutics Holdings Inc. (COEP) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COEP and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $34.48B.
- Over the past year, COEP is down 0.2% and RVMD is up 128.4% - RVMD leads by 128.6 points.
- RVMD has hit the wire 16 times in the past 4 weeks while COEP has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- Coeptis Therapeutics Holdings Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- -
- $34.48B
- 1M return
- +46.05%
- -17.91%
- 1Y return
- -0.18%
- +128.42%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 0
- 16
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest COEP
- SEC Form 4 filed by Coeptis Therapeutics Holdings Inc.
- Chief Executive Officer Halabu David Elias converted options into 19,737 shares (SEC Form 4)
- Director Sohn Adam Craig converted options into 1,370 shares (SEC Form 4)
- Director Fuerst Bryan Eric converted options into 1,370 shares (SEC Form 4)
- Director Cooper Kenneth Lyle converted options into 1,370 shares (SEC Form 4)
- Chief Technology Officer Harris Jeffery Keeslar converted options into 12,444 shares (SEC Form 4)
- Chief Financial Officer Cogley Brian converted options into 4,112 shares, increasing direct ownership by 18% to 26,612 units (SEC Form 4)
- Amendment: Chief Marketing Officer Schadel Christopher Ryan bought $3,920 worth of shares (1,000 units at $3.92) and converted options into 3,169 shares (SEC Form 4)
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Latest RVMD
- Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
- Officer Stephen Michael Kelsey exercised 27,160 shares at a strike of $18.56 and sold $4,559,209 worth of shares (27,160 units at $167.86) as part of a pre-agreed trading plan (SEC Form 4)
- Director Flavia Borellini exercised 2,500 shares at a strike of $37.54, increasing direct ownership by 10% to 28,715 units (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)